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Background: The aim of this study was to evaluate pre- and post-operative brain natriuretic peptide (BNP) levels
and compare the power of this test in predicting in-hospital major adverse cardiac events (MACE: atrial fibrillation,
flutter, acute heart failure or non-fatal/fatal myocardial infarction) in patients undergoing elective prosthesis
orthopedic surgery to that of the Revised Cardiac Risk Index (RCRI) and American Society of Anesthesiology (ASA)
class, the most useful scores identified to date.
Methods: The study was an observational study of consecutive patients undergoing elective prosthesis orthopedic
surgery. Surgical risk was established using RCRI score and ASA class criteria. Venous blood was sampled before
surgery and on postoperative day 1 for the measurement of BNP. The intraoperative data collected included details
of the surgery and anesthesia and any MACE experienced up until hospital discharge.
Results: MACE occurred in 14 of the 227 patients treated (6.2%). Age was statistical associated with MACE
(p < 0.004). Preoperative BNP levels were higher (p < 0.0007) in patients who experienced MACE than in event-free
patients (median values: 92 and 35 pg/mL, respectively). Postoperative BNP levels were also greater (p < 0.0001) in
patients sustaining MACE than in event-free patients (median values: 165 and 45 pg/mL, respectively). ROC curve
analysis demonstrated that for a cut-off point ≥ 39 pg/mL, the area under the curve for preoperative BNP was equal
to 0.77, while a postoperative BNP cut-off point ≥ 69 pg/mL gave an AUC of 0.82.
Conclusions: Both pre- and post-operative BNP concentrations are predictors of MACE in patients undergoing
elective prosthesis orthopedic surgery.
Keywords: Brain natriuretic peptide, Orthopedic surgery, Preoperative careBackground
The cardiopulmonary exercise test (CPET) is generally
considered as the “gold standard” in the assessment of
exercise capacity [1,2]. However, patients undergoing
elective major orthopedic surgery associated with severe
postoperative morbidity (including cardiac ischemic
events) may not able to undergo this or other subjective
measures of cardiorespiratory reserve, such as metabolic* Correspondence: vetrugno.luigi@aoud.sanita.fvg.it
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unless otherwise stated.equivalency tests (METs) [3,4], since mobility in these
patients may be limited [5]. Moreover, in patients at
increased risk of postoperative morbidity, non-invasive
stress testing (presumed to simulate the adrenergic
stress of surgery and the perioperative period) is expen-
sive and has been shown to have a low predictive posi-
tive value (i.e., it has a high false positive rate), which
might cause more harm than good [6,7]. To overcome
this limitation and to identify patients at increased risk
of postoperative morbidity, including cardiac events,
several surgical scoring systems have been developed,
such as the Revised Cardiac Risk Index (RCRI) [8], theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Survey [11]. But once again, the ability of such tests to
detect postoperative morbidity is only modest [9].
Brain natriuretic peptide (BNP) is a 32-amino acid
peptide containing a 17-amino acid ring structure
common to all natriuretic peptides. Measurement of
plasma levels of BNP or its N-terminal fragment
(NT-pro-BNP) is being increasingly used in the peri-
operative setting [12]. Recently, a number of studies
have examined the hypothesis that elevated preopera-
tive plasma concentrations of natriuretic peptides can
be used to identify patients at risk of adverse cardiac
events [13,14].
The aim of this study was to evaluate the power of
pre- and post-operative BNP levels to predict in-hospital
major cardiac events (MACE: atrial fibrillation or flutter,
acute heart failure, or non-fatal/fatal myocardial infarc-
tion) in patients undergoing elective prosthesis ortho-
pedic surgery, and to compare it to that of the RCRI and
American Society of Anesthesiology (ASA) class – the
most useful scores identified to date.
Methods
This study was approved by the Ethics Committee of the
University-Hospital of Udine “S. Maria della Misericor-
dia” and all patients gave their written informed consent
for participation. The study was an observational cross
study of consecutive patients undergoing elective pros-
thesis orthopedic surgery. Elective prosthesis orthopedic
surgery was defined as first implant of the hip or knee re-
placement. Patients were included if they were >50 years
of age and undergoing spinal anesthesia. Exclusion criteria
were: lack of consent, atrial fibrillation, a recent history
(within 6 months) of unstable coronary syndrome, or de-
compensate heart failure. Since severe aortic valve stenosis
and impaired renal function are associated with increased
serum levels of natriuretic peptides, patients with these
preoperative diagnoses were also excluded. Before surgery,
patients underwent routine clinical evaluation, including
the taking of a detailed medical history, a physical evalu-
ation, routine laboratory tests, 12-lead electrocardiography
and chest radiography. Clinically stable patients with cor-
onary artery disease proceeded to surgery without any fur-
ther non-invasive testing [15]. Surgical risk in each patient
was established using the criteria of the ASA [16] (the cri-
teria of this classification are well-known and patients are
classified as ASA I, II, III, IV or V) and the RCRI as de-
fined by Lee et al. [8]. Patients underwent venous blood
sampling in the morning of the pre-anesthesia visit (pre-
hospitalization). However, in cases in which this was not
possible, blood samples for assessing pre-operative BNP
were drawn on the same day as surgery. Postoperative
BNP was sampled in the morning of the first day after sur-
gery. Blood was collected in EDTA and lithium heparinvacutainer tubes, and immediately send to the laboratory
for analysis (by means of a specialized transport service
for biological materials) where BNP concentrations were
assayed using the Bayer ADVIA Centaur™.
The results of these tests were not known in real time
and investigators and patients were blind to the test
results. Anesthesia was conducted by consultant anes-
thetists. Intrathecal injections were performed in the
pre-operating room. Patients received either hyperbaric
bupivacaine 5 mg/mL (2 mL) (Angelini-A.C.R.A.F, Rome/
Italy) or isobaric levobupivacaine 5 mg/mL (Abbot S.r.l.,
Campoverde di Aprilia, Latina, Italy), according to the
anesthetist’s choice.
Perioperative data collection included details of the
surgery and anesthesia and any major adverse cardiac
events (MACE: new onset of atrial fibrillation, flutter,
acute heart failure or non-fatal/fatal myocardial infarc-
tion) occurring prior to hospital discharge. In particular,
postoperative acute myocardial infarction (AMI) was de-
fined for Troponin I (cTnI) concentrations ≥0.12 ng/mL
(3 times the 99th percentile upper reference limit (URL)
in patients presenting specific features (clinical or ECG
signs), in accordance with the definition of myocardial
infarction used in previous clinical investigations [17].
Pre- and post-operative creatinine, pre- and post-
operative hemoglobin (Hb), the lowest Hb value, the
number of transfusion units, and the overall surgical
time were recorded. Postoperative pain management
consisted of oral oxycodone 10 mg (BARD Pharmaceut-
ics Ltd., Cambridge, United Kingdom) and was adminis-
tered before and 12 hours after hip surgery, together
with 10–15 mg/kg i.v. acetaminophen (Fresenius Kabi S.r.l,
Verona, Italy), which was given every 6 hours. After knee
surgery, continuous femoral nerve blockade was obtained
using levobupivacaine 4 mg/hour, delivered through a
PlexoLong Nanoline Tuohy cannula (PAJUNK GmbH,
18G × 50 mm Medizintechnologie, Geisingen, Germany);
this perineuronal continuous infusion was used instead of
10 mg oral oxycodone.
For the entire sample, as well as for the sample stratified
for the presence or absence of MACE, median values (plus
IQR) were calculated for: age, gender, body mass index
(BMI), pre- and post-operative creatinine, pre- and post-
operative hemoglobin and its lowest intra-operative value,
transfusion units and surgical time; while percentage dis-
tributions were calculated for: RCRI score, ASA class,
length of stay (LOS), the presence of coexisting diseases,
and drugs. The percentage distributions for the continu-
ous variables in patients with MACE and in patients
without MACE were tested using Fisher’s exact t test or
the chi squared test. Pre- and postoperative BNP and the
other quantitative variables were investigated using the
non parametric Mann–Whitney U test for independent
samples for the two group considered. Receiver operating
Figure 1 Diagram of the patient flow through the study.
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under the curve (AUC) estimated to establish a cut-off of
the pre- and post-operative BNP values with appropriate
sensitivity and specificity to prevent MACE. The optimum
cut-off point was determined as the value corresponding
to the greatest accuracy (i.e. highest summed value for
sensitivity plus specificity values, with sensitivity and spe-
cificity weighted equally). ROC curves were also calculated
to establish the AUC for RCRI and ASA class. Univariate
logistic regression analyses were used to study how patient
variables, the presence of coexisting disease, and medi-
cation history influenced the occurrence of MACE.
Multiple logistic regression analysis was used to test the
predictive value of elevated BNP levels and other se-
lected parameters. Factors with a p-value <0.25 in uni-
variate analysis were entered into a multivariate model.
Finally, as described by Rodseth et al., patients were cat-
egorized according to their RCRI group (0 = low risk; 1
or 2 = intermediate risk; 3, 4 or 5 = high risk) and then
reclassified according to their preoperative BNP (above
or below the cut-off ) [18].
Our own pilot data [19] on vascular surgery patients
suggest that the incidence of AMI is around 11%, with
these patients presenting a mean preoperative BNP level
of 209 pg/mL (interquartile range, IQR: 84–346) com-
pared to 74 pg/mL (IQR: 28–142) in those who did not.
Thus, we calculate that a sample size of 200 patients
completing the study for preoperative BNP and 206 pa-
tients for postoperative BNP would allow us to detect a
30 pg/mL difference in BNP levels between patients who
did and those who did not experience acute myocardial
infarction, with 90% statistical power at the 5% signifi-
cance level. The software SAS 9.3 for Windows (SAS In-
stitute Inc., Cary, North Carolina, USA) was used for all
statistical analyses.
Results
Four-hundred-sixteen patients underwent elective pros-
thesis orthopedic surgery during the study period (July
2010 to June 2012). Of these, 318 patients were screened
for eligibility, of which 227 fulfilled the inclusion criteria
and were prospectively enrolled onto the study: 116 pa-
tients underwent hip replacement surgery and 111 knee
replacement surgery under spinal anesthesia, with 14 re-
quiring rescue (Figure 1). The demographic characteris-
tics, ASA class, RCRI, coexisting diseases, and medication
history for this cohort are shown in Table 1. Postoperative
MACE occurred in 14 of the 227 patients treated: 7 cases
of acute (non fatal) AMI; 5 cases of AF, and 2 cases of
bradycardia with new onset atrio-ventricular block. Of
the demographic variables, only age was significantly as-
sociated with MACE. Previous angina and previous
myocardial infarction showed only marginal association
(Table 1), as was also the case for lowest intra-operativehemoglobin level (Table 2). Preoperative BNP levels were
higher (p < 0.0007) in patients who experienced MACE
(median value 92 pg/mL, IQR: 45–143) than in event-free
patients (median value 35 pg/mL, IQR: 19–74). Postopera-
tive BNP levels were also greater (p < 0.0001) in patients
sustaining MACE (median 165 pg/mL, IQR: 71–214) than
in event-free patients (median value 45 pg/mL, IQR:
27–86; Figure 2 and Table 2). Analysis of the ROC curve
(Figure 3) demonstrates that for a cut-off point ≥ 39 pg/
mL, preoperative BNP showed a sensitivity of 93% and
specificity of 56% in predicting events, with an AUC of
0.77 (95% confidence interval (CI): 0.66 – 0.87). A post-
operative BNP cut-off point ≥ 69 pg/mL showed a sensi-
tivity of 86% and specificity of 68%, with an AUC of 0.82
(95% CI: 0.70 – 0.93). Patients who experienced MACE
(n = 14) remained in hospital for a median of 10 days
(IQR: 8–14) following their operation, compared with 8
(6–9) days in those who were event-free (p < 0.0016). Of
the 14 patients experiencing MACE, 10 were categorized
as ASA class II (71%), and 4 as class III (29%); statistical
analysis confirm a significant difference in the distribution
between the two groups (p < 0.05). When patients were
stratified by RCRI score, MACE events occurred more
frequently in patients with low or intermediated RCRI
Table 1 Patients population with and without MACE
Entire sample MACE NO MACE p value
n = 227 (n = 14) (n = 213)
Demographic characteristics
Age; yrs (median, IQR) 71 (66–76) 78 (74–82) 71 (66–75) 0.00041
Male; n (%) 90 (40) 3 (21) 87 (41)
0.152
Female; n (%) 137 (60) 11 (79) 126 (59)
BMI; Kg/m2 (median, IQR) 28 (25–31) 27 (25–29) 28 (25–31) 0.441
Obesity; n (%) 98 (43) 5 (36) 93 (44) 0.562
ASA class; n (%)
Class I 10 (4) 0 (0.00) 10 (4)
0.053Class II 184 (81) 10 (71) 174 (82)
Class III 33 (15) 4 (29) 29 (14)
RCRI; n (%)
0 165 (72.7) 7 (50) 158 (74.1)
0.093
1 44 (19.4) 4 (28.6) 40 (18.8)
2 10 (4.4) 2 (14.3) 8 (3.8)
3 7 (3.1) 1 (7.1) 6 (2.9)
4 1 (0.4) 0 (0.00) 1 (0.4)
Coexisting diseases; n (%)
Hypertension 169 (74) 12 (86) 157 (74) 0.173
Diabetes 40 (18) 3 (21) 37 (17) 0.723
Smokers 40 (18) 1 (7) 39 (18) 0.473
COPD 12 (5) 0 (0.00) 12 (5.6) 1.003
Previous angina 18 (8) 3 (21) 15 (7) 0.093
Previous AMI 17 (7) 3 (21) 14 (6.5) 0.073
Previous AF 15 (6.6) 2 (14) 13 (6.1) 0.233
Medication history; n (%)
ACE inhibitor 43 (19) 5 (36) 38 (18) 0.153
Aspirin 43 (19) 4 (29) 39 (18) 0.303
Beta-blockers 64 (28) 6 (43) 58 (28) 0.233
Ca antagonists 25 (11) 1 (7) 24 (11) 1.003
Diuretics 54 (24) 4 (29) 50 (23) 0.443
AR antagonist 67 (30) 3 (21) 64 (30) 0.843
Statins 45 (20) 2 (15) 43 (20) 0.743
P values indicate the significance of the association to MACE.
NOTE: The data are presented with median and interquartile range (IQR) or percentage (%).
Legend: MACE (major adverse cardiac event), ASA (American Society of Anesthesiology), BMI (Body mass index), RCRI (revised cardiac risk index), COPD (chronic
obstructive pulmonary disease), AMI (acute myocardial infarction), AF (atrial fibrillation), ACE (angiotensin-converting enzyme), AR (angiotensin receptor).
1P value derived using Mann–Whitney U test. 2P value derived using Chi-squared test for quantitative variables. 3P value derived Fisher’s exact test for
qualitative variables.
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ASA and RCRI to predict MACE gave AUC of 0.59
(95% CI: 0.47 – 0.71) and 0.63 (95% CI: 0.48 – 0.77), re-
spectively. Univariate regression analysis showed that
age (p < 0.001) and lowest intra-operative hemoglobin
level (p < 0.047) were statistically associated with MACE,
as were preoperative BNP concentrations ≥ 39 pg/mL(p < 0.0007) and postoperative BNP concentrations ≥
69 pg/mL (p < 0.0001). Multivariate regression analysis
showed that the preoperative variables with p values <0.25
were statistically different from age: odd-ratio (OR) of
1.114 (95% CI: 1.002 – 1.238); the same was true for
preoperative BNP concentrations ≥ 39 pg/mL: OR = 9.007
(95% CI: 1.051 – 77.191). In the postoperative period, only
Table 2 Pre- and postoperative blood tests, transfusion units, surgical time and LOS
Laboratory tests and intra-operative data Entire sample MACE NO MACE p value
(Median values, plus IQR) n = 227 (n = 14) (n = 213)
Preop. Creat (mg/dL) 0.93 (0.80-1.07) 0.95 (0.86-1.10) 0.92 (0.80-1.06) 0.49
Postop. Creat (mg/dL) 0.85 (0.72-0.98) 0.87 (0.74-0.93) 0.85 (0.72-0.99) 0.99
Preop. Hb (mg/dL) 13.5 (12.8-14.5) 13.15 (12.4-15.1) 13.50 (12.80-14.40) 0.99
Postop. Hb (mg/dL) 9.6 (8.6-11.3) 8.75 (7.4-10) 9.60 (8.60-11.30) 0.13
Lowest intraop. Hb (mg/dL) 11.1 (9.9-12.4) 10.05 (8.6-11.5) 11.15 (9.90-12.40) 0.08
BNP preop. (pg/mL) 36 (20–77) 92 (45–143) 35 (19–74) 0.0007
BNP postop. (pg/mL) 48 (28–97) 165 (71–214) 45 (27–86) 0.0001
Transfusion 0 (0–0) 0 (0–2) 0 (0–0) 0.18
Surgical time (min) 100 (75–120) 107 (85–150) 100 (75–120) 0.17
LOS (days) 8 (6–9) 10 (8–14) 8 (6–9) 0.0016
P values indicate the significance of the association to MACE.
Legend: Preop. (preoperative), Postop. (postoperative), Intraop. (intraoperative), Creat (creatinine), MACE (major adverse cardiac event), Hemoglobin (Hb), BNP
(Brain Natriuretic Peptide), LOS (Length of stay).
P value derived using Mann–Whitney U test.
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significant difference: OR = 6.371 (95% CI: 1.129 – 35.94).
All 227 patients were classified into 3 risk groups ac-
cording to their RCRI scores [18] (low 0, intermediate
1–2, high 3-4-5). A reclassification was also performed
on the basis of the preoperative BNP levels. If levels fell
below 39 pg/mL, patients were moved down by 1 risk
category, and if the levels rose above 39 pg/mL, patients
were moved up 1 risk category; Table 3 shows theFigure 2 Box plots of preoperative (Preop.) and postoperative (Posto
with the event-free patients (blue bars). P <0.0007 BNP Preop. vs P <0.0results of the reclassification process. Of the patients
originally classified into the low risk group, 40.6%
became reclassified as intermediate when considering
preoperative BNP. In patients classified into the inter-
mediate risk group, 37% became reclassified into the
low and 63% into the high risk group. Re-stratifying
according to preoperative BNP concentrations resulted in
a statistically significant improvement in discrimination
(Table 3).p.) BNP levels in the 14 patients with MACE (red bars) compared
001 Postop.
Figure 3 Receiver operating characteristic curve for preoperative (Preop.) and postoperative (Postop.) BNP levels and prediction of
in-hospital MACE (major cardiac evets). AUC = area under the curve, Ref. = reference line.
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cohort patients experienced acute respiratory failure (3
pneumonia and 2 acute pulmonary embolisms), four de-
veloped acute renal failure, 6 developed an infection (2
cases of early prosthesis infection and 4 cases of urinary
tract infection), and 5 patients developed neurological
dysfunctions. The results of the Chi Squared test show
that there is no statistically significant association between
the dichotomized preoperative BNP level and the occur-
rence of other (non-cardiac) complications (p = 0.8782).
Logistic regressions show that: i) preoperative BNP ≥
39 pg/dL does not increase the risk of further complica-
tions (OR = 0.919, 95% CI: 0.312 – 2.710); and ii) an
increase in preoperative BNP is not associated with a sta-
tistically significant higher risk of further complications
(OR = 0.996 95% CI: 0.991 – 1.001).
Discussion
The main findings of this study are two-fold: first, pre- and
post-operative BNP levels are predictors of perioperativeTable 3 Risk reclassification with preoperative BNP cutoff ≥ 3
RCRI risk category Entire sample MACE NO-M
Low risk 165 (72.7) 7 (50) 158 (7
Intermediate risk 54 (23.8) 6 (42.9) 48 (2
High risk 8 (3.5) 1 (7.1) 7 (3
Legend: RCRI (revised cardiac risk index), MACE (major adverse cardiac event).MACE in patients undergoing prosthesis elective ortho-
pedic surgery under spinal anesthesia; second, RCRI and
ASA appear to be inadequate predictors of postoperative
cardiac events in this form of elective surgery. The data
also confirm that in-hospital non-cardiac morbidity (acute
respiratory failure, acute renal failure, infections, and
neurological deficit) is more common than MACE (8.8%
versus 6.2%), as previously reported [10]. The use of object-
ive measures of cardiopulmonary reserve, including cardio-
pulmonary exercise testing, has been reported in the
orthopedic literature, but such methods are often deemed
to be impractical. For example, in a study of the patients
with end-stage arthritis of the hip and knee, only 60% were
able to undertake conventional bicycle ergometry [20].
Current international guidelines recommend that the sub-
jective assessment of functional capacity (METs) forms one
of the three key criteria in the decision-making process
underlying risk stratification prior to non-cardiac surgery
[15]. A functional capacity of <4 METs forms one of the
threshold values that direct a patient down the high risk9 pg/dL
ACE Reclassification RCRI MACE NO-MACE
4.1) 118 (52) 1 (7.1) 117 (55)
2.6) 67 (29.5) 6 (42.9) 61 (28.6)
.3) 42 (18.5) 7 (50) 35 (16.4)
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assessing exercise capacity in orthopedic patients plus the
cost and expertise required to carry out preoperative tests
both point to the need for an alternative objective testing
method for assessing perioperative risk.
BNP is a 32-amino acid peptide containing a 17-amino
acid ring structure common to all natriuretic peptides
[21,22]. BNP levels in adults strongly correlate with the
New York Heart Association (NYHA) functional classifi-
cation of patients with heart failure and have been shown
to act as an independent predictor of adverse outcome
[23]. N-terminal pro-brain natriuretic peptide (NT-pro-
BNP), an inactive by-product resulting from the synthesis
of BNP, is another member of the natriuretic peptide fam-
ily [21]. Measurement of either plasma BNP or NT-pro-
BNP levels is being increasingly used in the perioperative
setting [9,12,14]. Yeh and colleagues investigated patients
undergoing non-cardiac surgery and were the first to de-
scribe the capacity of NT-pro-BNP to predict the compos-
ite end-point of postoperative cardiac complications [24].
Breidthardt et al. studied patients undergoing “unselected”
orthopedic surgery and demonstrated that preoperative
BNP levels can predict short-term and long-term postop-
erative cardiac events, with ROC analysis giving an AUC
of 0.86 for preoperative BNP [25]. Moreover, in a recent
meta-analysis of pre- and post-operative BNP values,
Rodseth et al. found that patients with elevated postopera-
tive BNP concentrations were at increased risk of AMI,
cardiac failure and mortality at 30 days and even 180 days
after surgery [26]. The usefulness of preoperative BNP
measurements as a predictor of perioperative cardiac
events was also reported by Cuthbertson and co-workers,
who identified a cut-off of preoperative BNP > 40 pg/mL
to be associated with a 5-fold increase in the risk of de-
veloping either postoperative cTnI elevation > 0.32 ng/
mL or new ECG abnormalities [27]. Using the optimum
cut-off point, we identified a very similar preoperative
BNP threshold of ≥ 39 pg/mL, which was associated
with a 9-fold increase in MACE. We also found that a
postoperative BNP threshold of > 69 pg/mL corresponded
to a 6-fold increase in MACE risk. Univariate and multi-
variate analysis of the data gathered consistently identified
the demographic factor age to be an independent predictor
of MACE events, with an increase in the OR of 1.114 per
year. Our study is the first to examine the power of both
pre- and postoperative BNP levels in predicting MACE
in a selected population of patients undergoing elective
orthopedic prosthetic surgery. However, four other studies
have reported similar findings in the orthopedic setting.
Chong CP and colleagues reported their observations in
relation to NT-pro-BNP after emergency orthopedic-
geriatric surgery, with rates of in-hospital cardiac com-
plications and AMI of 26% and 13.4%, respectively [12].
It should be noted that the average age of theirpopulation was 79.9 ± 9.6 years. Oscarsson A. and col-
leagues investigated the utility of BNP to predict peri-
operative cardiac events in high-risk patients undergoing
major non-cardiac surgery [28]. Their patient population
fell into ASA class III or IV categories, and 49% of which
experienced a perioperative adverse cardiac event. Villa-
corta and co-workers investigated preoperative BNP in pa-
tients undergoing orthopedic elective surgery where 8% of
patients experienced a cardiac event [14]. They similarly
found ASA classification to be a poor predictor of cardiac
events. Finally, Montagnana and colleagues enrolled 37
patients undergoing major elective orthopedic surgery and
found that NT-pro-BNP levels were significantly increased
72 hours postoperatively compared to preoperative levels
and assumed it to be a consequence of fluid overload [29].
A recent meta-analysis raised concerns about the useful-
ness of the RCRI and the performance of non invasive
tests and imaging studies, as they revealed them to have a
low positive predictive value (PPV) [9]. Our study con-
firms this finding by revealing an AUC of just 0.63
(95% CI: 0.48 – 0.77) in the ROC curve analysis of RCRI,
in accordance with the results of recent publications
[10,28]. The low predictive power of RCRI indicated by
these studies supports the need for other objective mea-
sures to be explored. However, if RCRI is used, then a re-
classification of patients according to pre-operative BNP
levels should be performed, as discussed by Rodseth and
colleagues, in order to improve its power [18].
In summary, the present study indicates the assessment
of BNP to be more reliable than ASA and RCRI in pre-
dicting adverse cardiovascular outcomes following non-
cardiac surgery. We can therefore propose the following:
i) the preoperative BNP cut-off value provide a more suit-
able tool for the stratification of preoperative risk, and ii)
increased postoperative BNP levels could be used to signal
the need for hemodynamic optimization in the appropri-
ate setting and depending on the resources available.
Several limitations of the present study need to be ac-
knowledged: first of all, the number of clinical events is
relatively small and cardiovascular morbidity – specifically,
cardiac ischemia – was a relatively infrequent morbidity
domain (3%). In our population, the clinical relevance of
incidental rises in postoperative troponin is uncertain as is
the data regarding ejection fraction. We also exclude pa-
tients with impaired renal function and this could repre-
sent another limitation of the study because in clinical
practice renal failure is quite common. Last but not least,
our definition of MACE, which included atrial fibrillation
and flutter, was very broad.
Conclusion
In conclusion, our results show both pre- and post-
operative BNP to be predictors of MACE events. BNP
assessment should therefore be performed to help the
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of preoperative cardiovascular status in patients under-
going elective prosthesis orthopedic surgery. In our set-
ting, BNP did not predict all causes of morbidity well, as
was to be expected since it cannot capture risk factors
for non-cardiac causes of morbidity or other periopera-
tive complications.
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